Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial
A K Andreassen, B Andersson, F Gustafsson, H Eiskjaer, G Radegran, E Gude, K Jansson, D Solbu, V Sigurdardottir, S Arora, G Dellgren, L Gullestad, SCHEDULE Investigators, Stefan B Christensen, Charlotte Just, Nedim Selimovic, Entela Bollano, Sven-Erik Bartfay, Kristjan Karason, Smita Dutta Roy, Helena Rexius, Annie Janssen, Marita Rosenberg, Liselotte Persson, Björn Kornhall, Björn Ekmehag, Öyvind Reitan, Wenche Stueflotten, Anne Relbo, Ingelin Grov, Ingrid Erikstad, Ole Geir Solberg, Asgrimur Ragnarsson, Svend Aakhus, Richard Massey, A K Andreassen, B Andersson, F Gustafsson, H Eiskjaer, G Radegran, E Gude, K Jansson, D Solbu, V Sigurdardottir, S Arora, G Dellgren, L Gullestad, SCHEDULE Investigators, Stefan B Christensen, Charlotte Just, Nedim Selimovic, Entela Bollano, Sven-Erik Bartfay, Kristjan Karason, Smita Dutta Roy, Helena Rexius, Annie Janssen, Marita Rosenberg, Liselotte Persson, Björn Kornhall, Björn Ekmehag, Öyvind Reitan, Wenche Stueflotten, Anne Relbo, Ingelin Grov, Ingrid Erikstad, Ole Geir Solberg, Asgrimur Ragnarsson, Svend Aakhus, Richard Massey
Abstract
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart transplant recipients. Patients were assigned within 5 days posttransplant to low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n = 56), or standard-exposure cyclosporine (n = 59), with both mycophenolate mofetil and corticosteroids. In the everolimus group, cyclosporine was withdrawn after 7–11 weeks and everolimus exposure increased (6–10 ng/mL). The primary efficacy end point, measured GFR at 12 months posttransplant, was significantly higher with everolimus versus cyclosporine (mean ± SD: 79.8 ± 17.7 mL/min/1.73 m2 vs. 61.5 ± 19.6 mL/min/1.73 m2; p < 0.001). Coronary intravascular ultrasound showed that the mean increase in maximal intimal thickness was smaller (0.03 mm [95% CI 0.01, 0.05 mm] vs. 0.08 mm [95% CI 0.05, 0.12 mm], p = 0.03), and the incidence of cardiac allograft vasculopathy (CAV) was lower (50.0% vs. 64.6%, p = 0.003), with everolimus versus cyclosporine at month 12. Biopsy-proven acute rejection after weeks 7–11 was more frequent with everolimus (p = 0.03). Left ventricular function was not inferior with everolimus versus cyclosporine. Cytomegalovirus infection was less common with everolimus (5.4% vs. 30.5%, p < 0.001); the incidence of bacterial infection was similar. In conclusion, everolimus-based immunosuppression with early elimination of cyclosporine markedly improved renal function after heart transplantation. Since postoperative safety was not jeopardized and development of CAV was attenuated, this strategy may benefit long-term outcome.
Trial registration: ClinicalTrials.gov NCT01266148.
Source: PubMed